cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2020.6.n773cardio-773Research ArticleОБЗОРREVIEWВнеклеточный матрикс сердца и его изменения при фиброзе миокардаExtracellular matrix of the heart and its changes in myocardial fibrosisГриценкоО. В.GritsenkoO. V.

кардиолог

cardiologist

qritzenko.olesia@mail.ruЧумаковаГ. А.ChumakovaG. A.

профессор

cardiologist, professor

g.a.chumakova@mail.ruШевляковИ. В.ShevlyakovI. V.

кардиолог

cardiologist

preobrajensky89@mail.ruВеселовскаяН. Г.VeselovskayaN. G.

кардиолог

cardiologist

nadezhda100@rambler.ruКГБУЗ «Алтайский краевой кардиологический диспансер», Барнаул, РоссияРоссияKGBUZ "Altai regional cardiological dispensary", Barnaul, RussiaRussian FederationФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава России, Барнаул, РоссияРоссияFSBEI HE "Altai state medical University" Ministry of Health of Russia, BarnaulRussian FederationФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово, РоссияРоссияFSBSI "Research Institute of complex problems of cardiovascular diseases", Kemerovo, RussiaRussian Federation202007072020606107–112Copyright © Kardiomag, 20202020KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/773

В настоящее время в патогенезе сердечной недостаточности большое внимание уделяется нейрогуморальным изменениям. В результате активации нейрогуморальных факторов запускаются процессы, приводящие к изменению состава внеклеточного матрикса и, соответственно, к формированию фиброза миокарда. В данной статье рассматривается ряд факторов, непосредственно участвующих в процессах развития фиброза миокарда.

Neurohumoral changes have recently attracted much attention as a part of the pathogenesis of heart failure. Activation of neurohumoral factors triggers processes resulting in changes of extracellular matrix composition and, thus, development of myocardial fibrosis. This article addresses a number of factors that directly contribute to the development of myocardial fibrosis.

Фиброзфакторы ростасердечная недостаточностьFibrosisgrowth factorsheart failureконфликт интересов не заявленThe authors declare that they have no conflict of interest.ReferencesHeusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G et al. Cardiovascular remodelling in coronary artery disease and heart failure. The Lancet. 2014;383(9932):1933–43. DOI: 10.1016/S0140-6736(14)60107-0Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G et al. Cardiovascular remodelling in coronary artery disease and heart failure. The Lancet. 2014;383(9932):1933–43. DOI: 10.1016/S0140-6736(14)60107-0Liu T, Song D, Dong J, Zhu P, Liu J, Liu W et al. Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. Frontiers in Physiology. 2017;8:238. DOI: 10.3389/fphys.2017.00238Liu T, Song D, Dong J, Zhu P, Liu J, Liu W et al. Current Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure. Frontiers in Physiology. 2017;8:238. DOI: 10.3389/fphys.2017.00238Russian: Шишкова В.Н. Механизмы развития сердечно – сосудистых заболеваний при ожирении и инсулинорезистентности: фокус на атеротромботические осложнения. Российский кардиологический журнал. 2016;9:72-8. DOI: 10.15829/1560-4071-2016-9-72-78Shishkova V.N. Mechanisms of cardiovascular diseases development in obesity and insulin resistance: focus on atherothrombosis. Russian Journal of Cardiology. 2016;9:72–8. DOI: 10.15829/1560-4071-2016-9-72-78Gyöngyösi M, Winkler J, Ramos I, Do Q, Firat H, McDonald K et al. Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure. 2017;19(2):177–91. DOI: 10.1002/ejhf.696Gyöngyösi M, Winkler J, Ramos I, Do Q, Firat H, McDonald K et al. Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure. 2017;19(2):177–91. DOI: 10.1002/ejhf.696Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biology. 2018;68–69:490–506. DOI: 10.1016/j.matbio.2018.01.013Li L, Zhao Q, Kong W. Extracellular matrix remodeling and cardiac fibrosis. Matrix Biology. 2018;68–69:490–506. DOI: 10.1016/j.matbio.2018.01.013Horwich TB, Fonarow GC. Glucose, Obesity, Metabolic Syndrome, and Diabetes relevance to Incidence of Heart Failure. Journal of the American College of Cardiology. 2010;55(4):283–93. DOI: 10.1016/j.jacc.2009.07.029Horwich TB, Fonarow GC. Glucose, Obesity, Metabolic Syndrome, and Diabetes relevance to Incidence of Heart Failure. Journal of the American College of Cardiology. 2010;55(4):283–93. DOI: 10.1016/j.jacc.2009.07.029Russian: Лакомкин С.В., Скворцов А.А., Горюнова Т.В., Масенко В.П., Терещенко С.Н. Галектин-3 – новый маркер диагностики и прогноза хронической сердечной недостаточности. Кардиология. 2012;52(3):45-52Lakomkin S.V., Skvortsov A.A., Goryunova T.V., Masenko V.P., Tereshchenko S.N. Galectin 3 - a New Biomarker for Diagnostics and Outcome of Chronic Heart Failure. Kardiologiia. 2012;52(3):45–52.Асташкин Е.И., Глезер М.Г. Липотоксические эффекты в сердце, наблюдаемые при ожирении. Артериальная гипертензия. 2009;15(3):335-41. DOI: 10.18705/1607-419X-2009-15-3-335-341Astashkin E.I., Glezer M.G. Cardiac lipotoxic effects of obesity. Arterial Hypertension. 2009;15(3):335–41. DOI: 10.18705/1607-419X-2009-15-3-335-341Wende AR, Abel ED. Lipotoxicity in the heart. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2010;1801(3):311–9. DOI: 10.1016/j.bbalip.2009.09.023Wende AR, Abel ED. Lipotoxicity in the heart. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2010;1801(3):311–9. DOI: 10.1016/j.bbalip.2009.09.023Драпкина О.М. Чернова Е.М. Миопатия как побочный эффект терапии статинами: механизмы развития и перспективы лечения. Рациональная фармакотерапия в кардиологии. 2015;11(1):96-101Drapkina O.M., Chernova E.M. Myopathy as a side effect of statin therapy: mechanisms of development and prospects for treatment. Rational Pharmacotherapy in Cardiology. 2015;11(1):96–101.Lucas JA, Zhang Y, Li P, Gong K, Miller AP, Hassan E et al. Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. American Journal of Physiology-Heart and Circulatory Physiology. 2010;298(2):H424–32. DOI: 10.1152/ajpheart.00529.2009Lucas JA, Zhang Y, Li P, Gong K, Miller AP, Hassan E et al. Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. American Journal of Physiology-Heart and Circulatory Physiology. 2010;298(2):H424–32. DOI: 10.1152/ajpheart.00529.2009Blüher S, Mantzoros CS. Leptin in humans: lessons from translational research. The American Journal of Clinical Nutrition. 2009;89(3):991S-997S. DOI: 10.3945/ajcn.2008.26788EBlüher S, Mantzoros CS. Leptin in humans: lessons from translational research. The American Journal of Clinical Nutrition. 2009;89(3):991S-997S. DOI: 10.3945/ajcn.2008.26788EБелая Н.В. Механизмы ремоделировая миокарда при артериальной игпертензии. Международный медицинский журнал. 2006;2:15-8Belaya N.V. Myocardium remodeling mechanisms in arterial hypertension. International Medical Journal. 2006;2:15–8.Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M et al. Early Induction of Transforming Growth Factor-β via Angiotensin II Type 1 Receptors Contributes to Cardiac Fibrosis Induced by Long-term Blockade of Nitric Oxide Synthesis in Rats. Hypertension. 1998;32(2):273–9. DOI: 10.1161/01.HYP.32.2.273Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M et al. Early Induction of Transforming Growth Factor-β via Angiotensin II Type 1 Receptors Contributes to Cardiac Fibrosis Induced by Long-term Blockade of Nitric Oxide Synthesis in Rats. Hypertension. 1998;32(2):273–9. DOI: 10.1161/01.HYP.32.2.273Khan SA, Dong H, Joyce J, Sasaki T, Chu M-L, Tsuda T. Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β. Laboratory Investigation. 2016;96(7):773–83. DOI: 10.1038/labinvest.2016.52Khan SA, Dong H, Joyce J, Sasaki T, Chu M-L, Tsuda T. Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β. Laboratory Investigation. 2016;96(7):773–83. DOI: 10.1038/labinvest.2016.52Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Failure Reviews. 2014;19(2):173–85. DOI: 10.1007/s10741-012-9365-4Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Failure Reviews. 2014;19(2):173–85. DOI: 10.1007/s10741-012-9365-4Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology. 2011;51(4):600–6. DOI: 10.1016/j.yjmcc.2010.10.033Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. Journal of Molecular and Cellular Cardiology. 2011;51(4):600–6. DOI: 10.1016/j.yjmcc.2010.10.033Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2010;298(5):H1415–25. DOI: 10.1152/ajpheart.01048.2009Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2010;298(5):H1415–25. DOI: 10.1152/ajpheart.01048.2009Гавриленко Т.И., Рыжкова Н.А., Пархоменко А.Н. Сосудистый эндотелиальный фактор роста в клинике внутренних заболеваний и его патогенетическое значение. Украинский кардиологический журнал. 2011;4:87-95Gavrilenko T.I., Ryzhkova N.A., Parkhomenko A.N. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic value. Ukrainian Journal of Cardiology. 2011;4:87–95.Герштейн Е.С., Кушлинский Д.Н., Терешкина И.В., Ермилова В.Д., Овчинникова Л.К., Галдава Д.Э. и др. Фактор роста эндотелия сосудов и опухоли женской репродуктивной системы. Часть 1. Рак молочной железы. Онкогинекология. 2015;1:34-41Gershteyn E.S., Kushlinskiy D.N., Tereshkina I.V., Ermilova V.D., Ovchinnikova L.K., Galdava D.E. et al. Vascular Endothelial Growth Factor and the Tumors of Female Reproductive System. Part I. Breast Cancer. Gynecologic Oncology. 2015;1:34–41.Merentie M, Rissanen R, Lottonen-Raikaslehto L, Huusko J, Gurzeler E, Turunen MP et al. Doxycycline modulates VEGF-A expression: Failure of doxycycline-inducible lentivirus shRNA vector to knockdown VEGF-A expression in transgenic mice. PLOS ONE. 2018;13(1):e0190981. DOI: 10.1371/journal.pone.0190981Merentie M, Rissanen R, Lottonen-Raikaslehto L, Huusko J, Gurzeler E, Turunen MP et al. Doxycycline modulates VEGF-A expression: Failure of doxycycline-inducible lentivirus shRNA vector to knockdown VEGF-A expression in transgenic mice. PLOS ONE. 2018;13(1):e0190981. DOI: 10.1371/journal.pone.0190981Park J, Kim M, Sun K, An YA, Gu X, Scherer PE. VEGF-A–Expressing Adipose Tissue Shows Rapid Beiging and Enhanced Survival After Transplantation and Confers IL-4–Independent Metabolic Improvements. Diabetes. 2017;66(6):1479–90. DOI: 10.2337/db16-1081Park J, Kim M, Sun K, An YA, Gu X, Scherer PE. VEGF-A–Expressing Adipose Tissue Shows Rapid Beiging and Enhanced Survival After Transplantation and Confers IL-4–Independent Metabolic Improvements. Diabetes. 2017;66(6):1479–90. DOI: 10.2337/db16-1081Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K et al. Distinct Characteristics of Circulating Vascular Endothelial Growth Factor-A and C Levels in Human Subjects. PLoS ONE. 2011;6(12):e29351. DOI: 10.1371/journal.pone.0029351Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K et al. Distinct Characteristics of Circulating Vascular Endothelial Growth Factor-A and C Levels in Human Subjects. PLoS ONE. 2011;6(12):e29351. DOI: 10.1371/journal.pone.0029351Loebig M, Klement J, Schmoller A, Betz S, Heuck N, Schweiger U et al. Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men. PLoS ONE. 2010;5(9):e12610. DOI: 10.1371/journal.pone.0012610Loebig M, Klement J, Schmoller A, Betz S, Heuck N, Schweiger U et al. Evidence for a Relationship between VEGF and BMI Independent of Insulin Sensitivity by Glucose Clamp Procedure in a Homogenous Group Healthy Young Men. PLoS ONE. 2010;5(9):e12610. DOI: 10.1371/journal.pone.0012610Ylä-Herttuala S, Baker AH. Cardiovascular Gene Therapy: Past, Present and Future. Molecular Therapy. 2017;25(5):1095–106. DOI: 10.1016/j.ymthe.2017.03.027Ylä-Herttuala S, Baker AH. Cardiovascular Gene Therapy: Past, Present and Future. Molecular Therapy. 2017;25(5):1095–106. DOI: 10.1016/j.ymthe.2017.03.027Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F et al. Fibrosis imaging: Current concepts and future directions. Advanced Drug Delivery Reviews. 2017;121:9–26. DOI: 10.1016/j.addr.2017.10.013Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F et al. Fibrosis imaging: Current concepts and future directions. Advanced Drug Delivery Reviews. 2017;121:9–26. DOI: 10.1016/j.addr.2017.10.013Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cellular and Molecular Life Sciences. 2014;71(4):549–74. DOI: 10.1007/s00018-013-1349-6Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cellular and Molecular Life Sciences. 2014;71(4):549–74. DOI: 10.1007/s00018-013-1349-6Löfsjögård J, Kahan T, Díez J, López B, González A, Ravassa S et al. Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction. The American Journal of Cardiology. 2017;119(12):2042–8. DOI: 10.1016/j.amjcard.2017.03.036Löfsjögård J, Kahan T, Díez J, López B, González A, Ravassa S et al. Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients ≥60 Years With Heart Failure and Reduced Ejection Fraction. The American Journal of Cardiology. 2017;119(12):2042–8. DOI: 10.1016/j.amjcard.2017.03.036Madahar P, Duprez DA, Podolanczuk AJ, Bernstein EJ, Kawut SM, Raghu G et al. Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine. 2018;140:108–14. DOI: 10.1016/j.rmed.2018.06.001Madahar P, Duprez DA, Podolanczuk AJ, Bernstein EJ, Kawut SM, Raghu G et al. Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis. Respiratory Medicine. 2018;140:108–14. DOI: 10.1016/j.rmed.2018.06.001Рацина Е.В., Говорин А.В., Соколова Н.А., Фетисова Н.В. Динамика биомаркеров синтеза и деградации коллагена при остром трансмуральном переднем инфаркте миокарда, осложненном аневризмой. Сибирский медицинский журнал (Иркутск). 2014;130(7):23-6Ratsina E.V., Govorin A.V., Sokolova N.A., Fetisova N.V. Dynamics of collagen synthesis and degradation biomarkers in acute transmural anterior myocardial infarction complicated by an aneurysm. Siberian Medical Journal (Irkutsk). 2014;130(7):23–6.Eschalier R, Fertin M, Fay R, Bauters C, Zannad F, Pinet F et al. Extracellular Matrix Turnover Biomarkers Predict Long-Term Left Ventricular Remodeling After Myocardial Infarction: Insights From the REVE-2 Study. Circulation: Heart Failure. 2013;6(6):1199–205. DOI: 10.1161/CIRCHEARTFAILURE.113.000403Eschalier R, Fertin M, Fay R, Bauters C, Zannad F, Pinet F et al. Extracellular Matrix Turnover Biomarkers Predict Long-Term Left Ventricular Remodeling After Myocardial Infarction: Insights From the REVE-2 Study. Circulation: Heart Failure. 2013;6(6):1199–205. DOI: 10.1161/CIRCHEARTFAILURE.113.000403Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM et al. Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2009;119(18):2471–9. DOI: 10.1161/CIRCULATIONAHA.108.809194Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM et al. Extracellular Cardiac Matrix Biomarkers in Patients With Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction and Heart Failure: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2009;119(18):2471–9. DOI: 10.1161/CIRCULATIONAHA.108.809194de Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the Art: Newer biomarkers in heart failure: Newer biomarkers in heart failure. European Journal of Heart Failure. 2015;17(6):559–69. DOI: 10.1002/ejhf.273de Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the Art: Newer biomarkers in heart failure: Newer biomarkers in heart failure. European Journal of Heart Failure. 2015;17(6):559–69. DOI: 10.1002/ejhf.273Lupu S, Agoston-Coldea L. Soluble ST2 in Ventricular Dysfunction. In: Advances in Clinical Chemistry. - Elsevier;2015. - P.139-159. [ISBN: 978-0-12-802265-8; DOI: 10.1016/bs.acc.2014.12.005].Lupu S, Agoston-Coldea L. Soluble ST2 in Ventricular Dysfunction. In: Advances in Clinical Chemistry. - Elsevier;2015. - P.139-159. [ISBN: 978-0-12-802265-8; DOI: 10.1016/bs.acc.2014.12.005].Shah RV, Januzzi JL. Soluble ST2 and Galectin-3 in Heart Failure. Clinics in Laboratory Medicine. 2014;34(1):87–97. DOI: 10.1016/j.cll.2013.11.009Shah RV, Januzzi JL. Soluble ST2 and Galectin-3 in Heart Failure. Clinics in Laboratory Medicine. 2014;34(1):87–97. DOI: 10.1016/j.cll.2013.11.009Дылева Ю.А., Груздева О.В., Учасова Е.Г., Кузьмина А.А., Каретникова В.Н. Стимулирующий фактор роста ST2 в кардиологии: настоящее и перспективы. Лечащий врач. 2017;11:65-71Dyleva Yu.A., Gruzdeva O.V., Uchashova E.G., Kuzmina A.A., Karetnikova V.N. Stimulating growth factor ST2 in cardiology: the present and prospects. Treating doctor. 2017;11:65–71.Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation. 2007;117(6):1538–49. DOI: 10.1172/JCI30634Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation. 2007;117(6):1538–49. DOI: 10.1172/JCI30634Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Frontiers in Immunology. 2018;9:2432. DOI: 10.3389/fimmu.2018.02432Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Frontiers in Immunology. 2018;9:2432. DOI: 10.3389/fimmu.2018.02432Sánchez-Más J, Lax A, Asensio-López M del C, Fernandez-Del Palacio MJ, Caballero L, Santarelli G et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. European Journal of Clinical Investigation. 2014;44(7):643–51. DOI: 10.1111/eci.12282Sánchez-Más J, Lax A, Asensio-López M del C, Fernandez-Del Palacio MJ, Caballero L, Santarelli G et al. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. European Journal of Clinical Investigation. 2014;44(7):643–51. DOI: 10.1111/eci.12282

The authors declare that there are no conflicts of interest present.